PD-L1 testing based on the SP142 antibody in metastatic triple-negative breast cancer: summary of an expert round-table discussion
Por favor, use este identificador para citas ou ligazóns a este ítem:
http://hdl.handle.net/10347/24826
Ficheiros no ítem
Metadatos do ítem
Título: | PD-L1 testing based on the SP142 antibody in metastatic triple-negative breast cancer: summary of an expert round-table discussion |
Autor/a: | Peg, Vicente López García, María Ángeles Comerma, Laura Peiró, Gloria García-Caballero Parada, Tomás Concha López, Ángel Suárez Gauthier, Ana Ruiz, Irune Rojo, Federico |
Centro/Departamento: | Universidade de Santiago de Compostela. Departamento de Ciencias Morfolóxicas |
Palabras chave: | Antibody | Breast cancer | Diagnosis | Immunohistochemistry | Immunotherapy | PD-L1 | |
Data: | 2021 |
Editor: | Future Medicine |
Cita bibliográfica: | Future Oncology 2021 17:10, 1209-1218. https://doi.org/10.2217/fon-2020-1100 |
Resumo: | Triple-negative breast cancer (TNBC) is more aggressive than other breast cancer subtypes. TNBC is characterized by increased expression of Programmed Death-ligand 1 (PD-L1), a signal used by many tumors to escape the immune response. Expression of PD-L1 is a positive predictor of response to immunotherapy; therefore, it should be investigated in TNBC in order to select patients who may benefit from anti-PD-L1 therapies. While many PD-L1 assays are available, only the VENTANA platform with the anti-PD-L1 (SP142) antibody is licensed as a companion diagnostic device for selecting patients with metastatic/advanced TNBC who are candidates for treatment with atezolizumab. In this article, we provide a summary of an expert round-table discussion about PD-L1 testing, using the SP142 antibody in metastatic TNBC |
Versión do editor: | https://doi.org/10.2217/fon-2020-1100 |
URI: | http://hdl.handle.net/10347/24826 |
DOI: | 10.2217/fon-2020-1100 |
ISSN: | 1479-6694 |
E-ISSN: | 1744-8301 |
Dereitos: | © 2021 Federico Rojo (on behalf of all co-authors). This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ Attribution-NonCommercial-NoDerivatives 4.0 Internacional |
Coleccións
-
- CM-Artigos [43]
O ítem ten asociados os seguintes ficheiros de licenza: